T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · May 27, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how certain biological markers, called T2 biomarkers, can help predict whether patients with occupational asthma will experience improvement after they stop being exposed to harmful substances at work. Occupational asthma can develop when someone is exposed to certain triggers in their job, and while stopping the exposure can help, only about 30% of patients fully recover. Researchers want to see if measuring T2 biomarkers can help identify which patients are more likely to get better after they cease their exposure.
To participate in this study, you need to be over 18 years old and have been diagnosed with occupational asthma through a specific test. You should also have reduced or eliminated your exposure to the trigger causing your asthma. If you join the study, you will undergo a test to check how your lungs react and will have your T2 biomarkers measured. This research could lead to better ways of predicting recovery for people with occupational asthma in the future. The study is not yet recruiting participants, so keep an eye out for updates if you’re interested!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18
- • Diagnosis of occupational asthma by specific inhalation challenge
- • Exposure to sensitizing agent avoided or reduced
- • Able to understand the aims and risks of the research and to give free and informed consent
- • For women of childbearing age: effective contraception in progress.
- • Benefiting from social security coverage
- Exclusion Criteria:
- • Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
- • Subject under court protection
- • Subject under guardianship or curatorship
- • Pregnant or breast-feeding patient
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported